Impact of biologics on growth in children with juvenile idiopathic arthritis

Documenti analoghi

• PReS-FINAL-2133: Drug survival and switching of biological agents in systemic juvenile idiopathic arthritis
  di: Woerner, A, et al.
  Pubblicazione: (2013)
• Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
  di: Nemiche, O, et al.
  Pubblicazione: (2011)
• The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
  di: Trachana, M, et al.
  Pubblicazione: (2011)
• A biopsychosocial approach to parents of children with juvenile idiopathic arthritis
  di: Georgiadou, Z, et al.
  Pubblicazione: (2011)
• Switching to an alternative biological agent in juvenile idiopathic arthritis (II)
  di: Murias, S, et al.
  Pubblicazione: (2011)